There are many reasons why osteoarthritis (OA) might develop in the first place, the progression of the disease can vary dramatically between different individuals and their response to different treatments can similarly be quite distinct. With the greater understanding OA pathophysiology, OA can often be described as a spectrum of disease composed of different phenotypes. Some people have even described this as a mixed bag of disorders or falling under the osteoarthritis umbrella. By characterising OA into phenotypes, it helps to improve our knowledge of the disease, and ultimately enables targeted treatment based on the phenotype that a patient presents with. On this episode of Joint Action, we will be speaking to Dr Francis Berenbaum to learn more about osteoarthritis phenotypes, how they are identified and how this affects the management of OA. Dr. Berenbaum is Professor of rheumatology at Sorbonne Université and is the Director of the Department of Rheumatology at AP-HP Saint-Antoine Hospital in Paris, France. He is the national representative of bone and joint diseases at AVIESAN, the French Alliance for the Life Science and Health.  He is a member of the EULAR Public Affairs Group and is a former member of the EULAR Scientific Program committee in 2018-2020. He is a former president of OARSI (Osteoarthritis Research Society International) in 2008-2010 and of the French Society of Rheumatology in 2014-2016. He is Associate Editor of the Annals of the Rheumatic Diseases. Dr Berenbaum leads an experimental team at INSERM institute. His basic research interests include the understanding of relationships between metabolic diseases and osteoarthritis. His clinical research focuses on new targeted therapies for treating symptoms and structural changes in osteoarthritis. He is involved in several clinical trials either from public or private partners. He has published more than 300 peer-reviewed publications.RESOURCESJournal articlesOsteoarthritis and inflammation: a serious disease with overlapping phenotypic patternsThe Phenotypic Approach to Osteoarthritis: A Look at Metabolic Syndrome-Associated OsteoarthritisDeep phenotyping of osteoarthritis: a step forwardCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Like other chronic conditions, the symptoms of osteoarthritis tend to fluctuate. About 25-30% of people suffering from knee osteoarthritis also suffer from what we call OA “flares” or “exacerbations”. These “flares” are often described as temporary episodes of increased pain, stiffness and swelling, which may also be accompanied by other physical and psychological symptoms. “Flares” can cause considerable disruption to daily activities, sleeping and concentration and is a common complaint from those presenting to health professionals. Despite this, there is little known about what causes flares and how we can best manage them. On today’s episode of Joint Action, we will be speaking to Dr Martin Thomas to learn more about “flares”, their triggers and how to best manage them. Dr Martin Thomas is a clinical academic, working as a Research Fellow in the School of Medicine at Keele University in the UK and as a Specialist Musculoskeletal Physiotherapist in the NHS. After completing a degree in Human Movement Science at the University of Liverpool and a Masters in Sport Psychology from Liverpool John Moores University, he went on to qualify as a physiotherapist in 2007, also from the University of Liverpool. In 2009 he moved to Keele to undertake a PhD on the clinical epidemiology of symptomatic midfoot osteoarthritis. As a post-doctoral researcher, his primary focus is on leading and developing web-based cohort studies using self-controlled methodologies to examine flares of osteoarthritis. His flares work was funded by the NIHR through its School for Primary Care Research and through an Integrated Clinical Academic Programme Clinical Lectureship from the NIHR and Health Education England (www.nihr.ac.uk).RESOURCESInfographic on flaresCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Topics include fascinating facts about crocodiles, UnitedHealthcare's short-term insurance plans, sleep number smartbed, Plushcare's telehealth services. Host expresses gratitude to listeners for support, hints at upcoming partnerships and diverse topics for future episodes.

Despite the prevalence, impact and disability associated with osteoarthritis, it is still relatively poorly understood. New insights are affording a window into previously held strong beliefs that we now consider as misconceptions. Many people in the community simply believe that osteoarthritis is a consequence of getting older. Others believe that the joint has no capacity for repair and some have suggested that we should just use treatments widely used for other inflammatory rheumatic diseases. These misconceptions have consequences both in terms of language that is used - with terms such as "wear and tear", osteoarthrosis, and degenerative joint disease being widely used but notoriously inaccurate descriptors of this disease.On this episode of we discuss many of the misconceptions an myths about osteoarthritis including, osteoarthritis as an inevitable part of aging, the ability for cartilage to repair, "mechanoinflammation" and much more.Tonia Vincent studied medicine at UCL UK, qualifying in 1993. She trained as a junior doctor in London, later specialising in Rheumatology. In 1998 she took time out to do a PhD at the Kennedy Institute of Rheumatology under Professor Jeremy Saklatvala (awarded 2002). She continued at the Kennedy Institute as a Wellcome Trust clinician scientist and subsequently as an Arthritis Research UK Senior Fellow. In 2012 the Kennedy Institute moved to the University of Oxford and she was appointed Professor of Musculoskeletal Biology. She directs the Centre for OA Pathogenesis funded by Versus Arthritis. Her research interests include pathways that drive mechanosensitive responses in cartilage, the role of the pericellular matrix in determining these responses and how they modulate osteoarthritis in vivo. Her work is funded by Versus Arthritis, MRC, ERC and the Kennedy Trust for Rheumatology Research. She continues to be clinically active, running both osteoarthritis clinics and the multidisciplinary Marfan Syndrome clinic. CONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Osteoarthritis is a frequent reason for patients to visit their GP or primary care practitioner, and the predominant reason they would do so is because of increasing difficulty with activities and pain. GPs are often the primary person into many healthcare systems and are typically visited before seeing any other health care practitioner for exercise, diet or surgery. Patients with osteoarthritis often have other serious commodities and the modern health care system typically does not afford long appointments which address behaviour change, shared decision making and counselling which leads patients to receive adequate, coordinated and appropriate care. On this week's episode of Joint Action we discuss what you should expect from your GP, including how to optimise your visit with your GP, tools to help healthcare practitioners and patients to make appropriate intervention choices and much more. Dr. Regina Sit obtained her Bachelor of Medicine and Bachelor of Surgery degree from the University of Hong Kong. She became a Family Medicine Specialist of the Hong Kong Academy of Medicine since 2011. In addition to her specialist training, she also carries qualifications in pediatrics, dermatology, geriatric and internal medicine. As a Family Physician, she develops her special skills in pain management and is a Certified Interventional Pain Sonologist by the World Institute of Pain. Her clinical and research interests focus on the study of musculoskeletal pain in primary care. She is passionate about exploring, designing, evaluating and implementing innovative interventions to improve the quality of life of those who suffer from chronic musculoskeletal pain. Currently, she is the director of the “CUHK-Jockey Club Pain Relief Project for the Seniors”, and is leading an interdisciplinary team for chronic pain management in primary care.George Peat is a Professor in Clinical Epidemiology at Keele University. George qualified as a physiotherapist in 1991 from Queen Margaret College, Edinburgh, before going on to gain a Masters in Public Health Sciences at Edinburgh University and PhD in 1998 from Manchester University. He later joined the Arthritis Research UK Primary Care Centre at Keele University in 1999.RESOURCESKeele University Impact Accelerator UnitVersus ArthritisCUHK-Jockey Club Pain Relief Project for the Seniors - Youtube Channel for exercise (in Cantonese)Journal ArticlesPatients' and practitioners' views of knee osteoarthritis and its management: a qualitative interview studyPatient reported barriers and facilitators to using a self-management booklet for hip and knee osteoarthritis in primary care: results of a qualitative interview studyWhat influences patients with osteoarthritis to consult their GP about their symptoms? A narrative reviewComparison of patient experiences of the osteoarthritis consultation with GP attitudes and beliefs to OA: a narrative reviewThe Identity Crisis of Osteoarthritis in General Practice: A Qualitative Study Using Video-Stimulated RecallThe relative importance of perceived doctor's attitude on the decision to consult for symptomatic osteoarthritis: a choice-based conjoint analysis studyCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

About 70% of people living with osteoarthritis are reported to be taking some form of complementary or alternative medicine for their osteoarthritis. The most common products are fish oil, glucosamine, vitamin D, chondroitin and herbal medicines. This is a very controversial area with differences between what is recommended by physicians, international guidelines, industry and marketing and then ultimately what people actually take for their osteoarthritis. On this episode of Joint Action, we are joined by Dr Jeffry Strong, a scientific director of a supplement company, as well as Hugh Amoyal, to provide a consumer perspective. On this episode of we discuss: what are natural supplements and how do they differ from other commonly used treatment options, what to consider before purchasing and incorporating natural supplements into your routine and much more.Dr Jeffry Michael Strong MD is a naturopathic physician trained in primary care medicine with special interests in complementary and alternative medicine, sports nutrition, diabetes, cardiovascular health. Dr Strong is currently serving as Scientific Director in the Asia region and Japan Country Manager for Horphag Research. He is fluent in Japanese.RESOURCESDietary supplements for treating osteoarthritis: a systematic review and meta-analysisNational Center for Complementary and Integrative Health - Know the Science webpageIntegrative Therapeutics - Drug-Nutrient InteractionsSeven questions to identify health misinformation in digital and social mediaCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

The first line pain relieving medication recommended in most therapeutic guidelines for osteoarthritis is the anti-inflammatory group of medications. They consistently demonstrate modest effects for relieving pain and improving function, pretty much irrespective of the site of osteoarthritis whether that be the hand, knee or hip. There is a huge variety of anti-inflammatories available, different routes of administration including oral and topical, different dosage strengths along with other elements that influence patient preference. On this episode we discuss: what are non-steroidal anti-inflammatory drugs (NSAIDs) and how do they work, what are the side effects of taking NSAIDs and how often do these occur, how efficacious are NSAIDs for pain relief and much moreProf Ric Day AM (MBBS, FRACP, MD) is internationally and nationally recognised for his research, leadership and advocacy in support of quality use of medicines (QUM). He has been deeply involved in Australia’s National Medicines Policy and the quality use of medicines component culminating in his Chairmanship of the Pharmaceutical Health and Rational Use of Medicines Committee (PHARM) for the Federal Government in 1999-2008. His research focuses on quality use of medicines and methods of enhancing the safe use of medicines using eHealth systems and decision support tools He has published over 600 peer reviewed papers. His current collaborations have lead to significant work investigating the potential of eHealth tools to increase medication safety but he has other significant areas of research. Prof Day is a committed undergraduate & post-graduate teacher & research mentor. Prof Day has received many awards, including Member of the Order of Australia AM. RESOURCESNPS MedicinewiseArthritis AustraliaThis Way UpCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Osteoarthritis is an extraordinarily prevalent and disabling disease. The prevalence appears to be increasing, in large part compounded by the ageing of the population but also with major contributions from demographic shifts as it relates to obesity are leading to increasing numbers of people with osteoarthritis. The two biggest risk factors for knee osteoarthritis are obesity and overweight and joint injury. They account for approximately 75% of a person’s likelihood of developing osteoarthritis of the knee. Both are eminently modifiable but from a public health perspective, we do very little if anything about modifying either. On this episode we discuss: risk factors for developing osteoarthritis, how much weight to lose to reduce their risk of developing osteoarthritis, the effects of weight loss on osteoarthritis and much more. Dr Jos Runhaar is an Assistant Professor at the Department of General Practice of Erasmus MC. NetherlandsHe was trained as Human Movement Scientist at the Vrije University Amsterdam. For his PhD, he performed the first ever trial on the primary prevention of osteoarthritis, supervised by Prof. Bierma-Zeinstra and Prof. Koes. The research direction of Dr. Runhaar aims to improve the diagnosis and treatment of musculoskeletal disorders by general practitioners and physiotherapists and to shift the treatment of musculoskeletal disorders to the early disease phase. RESOURCESJournal articlesWhat if we prevent obesity? Risk reduction in knee osteoarthritis estimated through a meta-analysis of observational studiesCurrent evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysisTo what extent is severe osteoarthritis preventable? Occupational and non-occupational risk factors for knee and hip osteoarthritisPrevention of Incident Knee Osteoarthritis by Moderate Weight Loss in Overweight and Obese FemalesLong-term effects of a randomized, controlled, tailor-made weight-loss intervention in primary care on the health and lifestyle of overweight and obese womenPredicting Knee Pain and Knee Osteoarthritis Among Overweight WomenCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! :) Hosted on Acast. See acast.com/privacy for more information.

Current management approaches for osteoarthritis are usually targeted to symptoms. One way to mitigate the epidemic of osteoarthritis is to modify both its structural progression and symptomatic consequences in tandem a method known as disease modification, as distinct from symptom modification. These could potentially slow the speed of disease progression, completely halted or in an ideal world reverse the disease and regenerate the target tissue. At present, despite a number of positive trials there are no drugs that have garnered regulatory approval for this indication. On this week's episode we discuss: what is disease modification, what have the clinical trials shown, what will the future of DMOADs look like and much more.Christoph Ladel is working as Translational Medicine Expert. Most recent position was as team lead in the global clinical development department in Merck Healthcare KGaA (Darmstadt, Germany). In his role he was involved in design and execution of clinical studies from phase 1 to phase 3. Special responsibility was in the field of biomarker and imaging (MRI and x-ray) read-outs in clinical studies, mainly in osteoarthritis. He contributed to the respective teams to analyze data and to develop further stratification strategies based on biomarkers (incl. imaging) for studies in osteoarthritis. Christoph trained as an immunologist with a PhD in immunopharmacology and immunotoxicology Dr Ladel has worked in different companies and different countries. Over the >15 years he was part of project teams or team leader in different projects for the discovery and development of therapies in osteoarthritis. Christoph is an internationally recognized scientist and has authored > 50 scientific peer reviewed publications and is co-inventor in more than 10 patents in the field of clinical strategies for osteoarthritis.RESOURCESDavid's presentation on DMOADS for the Arthritis Web Seminar Series at UHNWikipedia page on DMOADSJournal articlesCurrent status and future prospects for disease modification in osteoarthritisIntra-articular therapies for osteoarthritisEmerging drugs for the treatment of osteoarthritisCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Elena Losina, an expert in the economic burden of osteoarthritis, discusses the high costs of living with OA, including direct healthcare expenses and lost productivity. She emphasizes the need for cost-effective treatments and efficient healthcare resource allocation to optimize outcomes for individuals with osteoarthritis.